Biocon has presented the results of Phase I studies on the oral insulin product-IN-105 at the European Association for Study of Diabetes
Biocon Ltd, India’s premier biotechnology company, has presented the results of Phase I studies on the oral insulin product-IN-105 at the European Association for Study of Diabetes (EASD) meeting held at Amsterdam. Phase I studies were conducted on healthy volunteers who have been administered IN-105 in the form of a tablet. The human clinical data on IN-105 was presented at the session on novel therapies.
IN-105 is a novel analog of insulin, proprietary to Biocon. The product has special properties that make it feasible for delivery of insulin in tablet form, stable at room temperature. Besides being a needle free insulin, this method of delivery allows IN-105 to be delivered into the body in a physiological manner that mimics the way that the pancreas release insulin into the circulation. This contrasts with all the other known method of delivery.
Earlier Biocon had launched the recombinant insulin, Insugen which has already overtaken brand leaders both in some of the domestic markets as well as few international markets.